生物活性：Flumatinib-d3 is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively[1].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Flumatinib-d3 相关抗体:
c-Kit Antibody (YA502)
Phospho-PDGFR beta (Y740) Antibody
PDGFR alpha Antibody
PDGF B Antibody (YA1556)
PDGFR beta Antibody (YA1925)
Bcr Antibody (YA2746)
Phospho-PDGFR beta (Tyr740) Antibody (YA3062)
ABL2 Antibody (YA3203)
c-Kit Antibody
SCF Antibody
BLNK Antibody (YA2282)
BMF Antibody (YA2436)
CrkL Antibody (YA2577)
ABI2 Antibody (YA2840)
分子量：565.61
Formula：C29H26D3F3N8O
非标记 CAS：895519-90-1
中文名称：氟马替尼-d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (526 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Luo H, et al. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. Leukemia. 2010 Oct;24(10):1807-9.
 [Content Brief]
[3]. Zhao J, et al. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2013 Nov 10.
 [Content Brief]
[4]. Gong A, et al. Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients. Drug Metab Dispos. 2010 Aug;38(8):1328-40.
 [Content Brief]